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We describe the ﬁrst example of combining bacterial artiﬁcial chromosome (BAC) recombination-
mediated mutagenesis with reverse genetics for a negative strand RNA virus. A BAC-based respiratory
syncytial virus (RSV) rescue system was established. An important advantage of this system is that RSV
antigenomic cDNA was stabilized in the BAC vector. The RSV genotype chosen was A2-line19F, a
chimeric strain previously shown to recapitulate in mice key features of RSV pathogenesis.
We recovered two RSV reporter viruses, one expressing the red ﬂuorescent protein monomeric
Katushka 2 (A2-K-line19F) and one expressing Renilla luciferase (A2-RL-line19F). As proof of principle,
we efﬁciently generated a RSV gene deletion mutant (A2-line19FDNS1/NS2) and a point mutant (A2-K-
line19F-I557V) by recombination-mediated BAC mutagenesis. Together with sequence-optimized
helper expression plasmids, BAC-RSV is a stable, versatile, and efﬁcient reverse genetics platform for
generation of a recombinant Pneumovirus.
& 2012 Published by Elsevier Inc.Introduction
Respiratory syncytial virus (RSV) is the most important lower
respiratory tract pathogen of infants, but there are no effective
vaccines or antivirals in use. RSV is a member of the Paramyx-
oviridae family, genus Pneumovirinae, containing a non-segmen-
ted, negative-sense RNA genome (Collins and Crowe, 2007).
Plasmid-based reverse genetics and virus rescue is a cornerstone
of RSV research and vaccinology (Collins et al., 1995; Karron et al.,
2005). However, plasmid-based virus rescue systems for the
Pneumovirinae are plagued by cDNA instability (Biacchesi et al.,
2007; Moore et al., 2009). RSV rescue involves co-transfection of
an antigenomic cDNA plasmid in addition to four expression
plasmids encoding the RSV nucleoprotein (N), phosphoprotein
(P), large polymerase (L), and matrix 2-1 protein (M2-1) (Collins
et al., 1995; Jin et al., 1998). Current published rescue cDNA
plasmids encode antigenome of the reference A2 strain of RSV
(Collins et al., 1995; Jin et al., 1998). The proteins expressed fromElsevier Inc.
Infectious Diseases, Emory
E Room 514, Atlanta,
oore).the helper plasmids also are based on the genes from strain A2
(Collins et al., 1995; Jin et al., 1998). We chose RSV strain A2-
line19F for reverse genetics because infection with this chimeric
strain better recapitulates RSV pathogenesis in the mouse model
(Moore et al., 2009). We chose a bacterial artiﬁcial chromosome
(BAC) as the backbone vector because BACs and other low copy
vectors enhance stability of cDNAs that are difﬁcult to clone
(Almazan et al., 2000; Fan and Bird, 2008; Hall et al., 2012; Yun
et al., 2003; Zhou et al., 2011). Our BAC-RSV was used successfully
to directly transfect mammalian cells and recover recombinant
virus. We utilized this new BAC-RSV construct for recombination-
mediated genetic engineering to generate RSV mutants (Fig. 1).
This BAC-RSV mutagenesis system provides an improved platform
for RSV reverse genetics that could be applied to other RNA
viruses as well.Results
Sequence-optimized RSV N, P, M2-1, and L genes direct greater RSV
transcription than wild-type RSV genes
Efﬁcient recombinant RSV recovery requires co-transfection
with helper plasmids encoding the RSV N, P, M2-1, and L proteins
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Fig. 1. Model of RSV-BAC recombination-mediated mutagenesis and reverse
genetics. (A) First recombination step in which a double stranded PCR product
containing the galK cassette recombines with RSV antigenome sequence, based on
50 base-pair homology sequence ﬂanking galK. In the second step, annealed
oligonucleotides containing the desired mutation ﬂanked by the same 50 base-
pair homology arms recombines with the RSV antigenome to displace galK.
(B) RSV reverse genetics scheme. The RSV-BAC and sequence-optimized helper
plasmids encoding RSV N, P, M2-1, and L are transfected into BSR-T7/5 cells, and
infectious virus is recovered.
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Fig. 2. Sequence-optimized RSV helper plasmids drive more minigenome activity
than wild-type RSV helper plasmids. Minigenome activity driven by wild-type or
sequence-optimized helper plasmids. Results are from transfection using 0.8, 0.4,
0.4, 0.4, and 0.2 mg of minigenome, N, P, M2-1, and L respectively. Data are shown
as mean7SEM. Po0.05 by ANOVA of sequence-optimized relative to other
conditions.
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Sequence optimization of RSV cDNA for human codon bias and
other optimal features enhances cDNA expression in mammalian
cells (Huang et al., 2010). Plasmids encoding the wild-type
(non-optimized) N, P, M2-1, and L genes have been used pre-
viously to drive minigenome expression (Grosfeld et al., 1995).
Using an RSV-luciferase minigenome assay in BSR-T7/5 cells
(Dochow et al., 2012), we compared the activity of these wild-
type helper plasmids to the activity of plasmids that encode
sequence-optimized N, P, M2-1, and L genes (Dochow et al.,
2012). Compared to wild-type RSV cDNAs, the sequence-
optimized helper plasmids yielded approximately three fold
higher polymerase activity, based on a RSV minigenome contain-
ing a luciferase reporter gene (Fig. 2).
Generation of BAC-RSV reporter viruses
Antigenomic cDNA of A2-line19F was synthesized in three
segments. We cloned the three segments sequentially into the
BAC vector pKBS2 to generate the plasmid pSynkRSV-line19F.
An additional gene was included in the RSV antigenomic cDNA to
enhance detection of infection. The gene for the far-red ﬂuores-
cent protein monomeric Katushka 2 (mKate2) lies in the ﬁrst gene
position ﬂanked by RSV regulatory elements (Shcherbo et al.,
2009). The features of pSynkRSV-line19F are delineated by
nucleotide position in Table 1. We compared recovery efﬁciency
of the previously published RSV strain A2 antigenomic clone D46/
6120 with recovery of pSynkRSV-line19F, and there was nodifference in the recovery efﬁciency as measured by time
(in days) to rescue (data not shown). We also compared the
efﬁciency of pSynkRSV-line19F rescue using wild-type or sequence-
optimized helper plasmids. In replicate experiments, sequence-
optimized helpers yielded two-fold higher levels (0.5% of cells
compared to 0.2%) of mKate2 ﬂuorescence three days after trans-
fection, but there was no signiﬁcant difference in time to rescue
between wild-type and sequence-optimized helpers. We used the
sequence-optimized helper plasmids and pSynkRSV-line19F to
recover recombinant virus A2-K-line19F. Virus-encoded mKate2
serves as a marker for infected cells and provides means to assay
infected cells by ﬂuorescence (Fig. 3A and B). HEp-2 cell monolayer
cultures were infected with RSV A2-line19F or A2-K-line19F then
ﬁxed and immunostained 48 h post-infection (Fig. 3A). In addition,
the percentage of cells expressing RSV F (fusion protein) and
mKate2 was quantiﬁed using ﬂow cytometric analysis at 24 h
post-infection (Fig. 3B). F protein positive cells were detected by
indirect immunoﬂuorescence using a monoclonal antibody to RSV
F, while mKate2 ﬂuorescence was directly detected in infected cells.
mKate2 is a rapid and sensitive marker of infected cells, and is
detectable using ﬂuorescence microscopy and ﬂow cytometry
(Fig. 3).
Introduction of foreign genes into the RSV genome can
attenuate RSV growth (Bukreyev et al., 1996). We performed
virus high and low multiplicity replication analyses of A2-K-
line19F and A2-line19F. A2-K-line19F grew to similar titers as
A2-line19F in HEp-2 cell monolayer cultures (Fig. 4A and B). We
inserted the Renilla luciferase gene into pSynkRSV-line19F in
place of the gene for mKate2 and recovered A2-RL-line19F virus.
Multi-step replication analysis in HEp-2 cell monolayer cultures
showed that A2-RL-line19F grew to similar titers as A2-K-line19F
in this cell line (Fig. 4C). We then used the A2-RL-line19F virus in
a replication assay to determine how the titer of live virus
detected as plaque forming units correlated with luciferase
activity. The lowest levels of luciferase activity correlated with
the lowest viral titers, and the highest levels of luciferase activity
correlated with the peak viral titers (Fig. 4C). Virus-directed
protein expression occurs prior to virus particle assembly, conse-
quently, luciferase activity neared its maximum levels at an
earlier time than virus titer (Fig. 4C). We next compared the lung
Table 1
Nucleotide sequence positions of features in pSynkRSV-line19F.
Nucleotide position Feature Reference
1–26 phi 10 T7 promoter Studier et al., (1990)
30–77 Hammerhead ribozyme Kwilas et al. (2010), Walker et al. (2003)
78–121 RSV leader Mink et al. (1991)
122–131 NS1 gene start Collins and Wertz (1985)
132–163 NS1 non-coding Collins and Wertz (1985)
164–874 mKate2 gene Shcherbo et al. (2009)
875–886 L noncoding Stec et al. (1991)
887–898 L gene end Stec et al. (1991)
899–917 NS1/NS2 intergenic Collins et al. (1987)
918–1391 NS1 gene Collins and Wertz (1985)
1392–1468 NS1/NS2 intergenic Collins et al., 1987
1469–1971 NS2 gene Collins and Wertz (1985)
1972–1996 NS2/N intergenic Collins et al. (1995)
1997–3200 N gene Collins et al. (1987)
3201–4115 P gene Collins et al. (1987)
4116–4124 P/M intergenic Moudy et al. (2004)
4125–5081 M gene Collins et al. (1987)
5082–5100 M/SH intergenic Collins et al. (1987)
5101–5399 SH gene Collins et al. (1990)
5400–5445 SH/G intergenic Collins et al. (1987)
5446–6368 G gene Collins et al. (1987)
6369–6419 G/F intergenic Collins et al. (1987)
6420–8322 F gene Moore et al. (2009)
8323–8368 F/M2 intergenic Johnson and Collins (1988)
8369–9329 M2 gene Collins et al. (1987)
9261–15839 L gene Stec et al. (1991)
15840–15993 RSV trailer Kwilas et al. (2010), Mink et al. (1991)
15994–16078 Hepatitis delta virus ribozyme Perrotta and Been (1991)
16079–16201 T7 terminator Studier et al. (1990)
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BALB/c mice. The lung viral load of A2-K-line19F was similar to
that of A2-line19F at day 4 post-infection, while lung viral load of
A2-RL-line19F was signiﬁcantly lower than both A2-line19F and
A2-K-line19F (Fig. 4D). These results indicate that mKate2 did not
cause growth restriction in vitro or in vivo. In addition, the
luciferase encoded by A2-RL-line19F provides a useful tool for
detecting virus infection in vitro, even though the A2-RL-line19F
was slightly restricted in replication in BALB/c mice.
BAC-RSV is a stable platform for subcloning and for recombination-
mediated genetic engineering
We determined the efﬁciency of cloning for an unstable
fragment of RSV cDNA. A high-copy number cloning vector
containing RSV cDNA including part of the small hydrophobic
(SH) gene, the attachment glycoprotein (G), F, and M2 genes, and
part of the L gene was transformed into two competent E. coli cell
strains. None of the transformants selected contained the correct
vector/insert. In contrast, when the same cDNA fragment of RSV
cDNA was cloned into BAC vector pKBS2, all of the transformant
colonies analyzed contained the correct vector/insert DNA. The
enhanced stability of RSV cDNA provided by the BAC allowed for
more efﬁcient cloning.
We sought to develop recombination-mediated mutagenesis
for RSV using a method relying on positive and negative selection
of the galK cassette (Warming et al., 2005). To demonstrate its
utility for RSV reverse genetics, we used this method to delete the
genes for the RSV nonstructural proteins NS1 and NS2. The gene
deletions were conﬁrmed by nucleotide sequence determination,
and lack of NS1 and NS2 production was conﬁrmed by Western
blot analysis of infected cell lysates (Fig. 5). We also used this
recombination-based mutagenesis to generate a point mutation
in the F protein of pSynkRSV-line19F, creating mutant I557V. The
sequence of the F gene was conﬁrmed to contain the correctmutation, demonstrating that recombination-mediated mutagen-
esis is a powerful tool for reverse genetic manipulations.Discussion
We have assembled the ﬁrst BAC recombination-mediated
mutagenesis system for reverse genetics of a negative strand RNA
virus. pSynkRSV-line19F is a RSV cDNA-containing BAC that is
highly stable and enhances the efﬁciency of RSV reverse genetics.
Recombination-mediated genetic engineering is commonly used for
large BAC clones and reverse genetics of DNA viruses (Donofrio
et al., 2007; Moyer et al., 2011). We demonstrated the utility of the
BAC-RSV mutagenesis system by generating viruses with either
gene deletions or a point mutation. We demonstrated the advan-
tage of using sequence-optimized helper plasmids for virus recov-
ery. These aspects of our reverse genetics system are likely to
enhance rescue of attenuated mutants. We recovered two reporter
viruses, A2-K-line19F and A2-RL-line19F, which express mKate2
and Renilla luciferase, respectively. Although these recombinant
viruses encoding reporter genes were attenuated in mice, we were
able to demonstrate their utility in vitro.
Stable and efﬁcient mutagenesis of the RSV-BAC construct will
facilitate RSV research and vaccine development. Despite the high
clinical signiﬁcance of RSV, reverse genetics reagents for this virus
are not in widespread use relative to other members of the
Mononegavirales, potentially due to cloning obstacles. BAC-RSV
cloning alleviates cDNA instability, enhances the efﬁciency of
traditional cloning, and enables recombination-mediated muta-
genesis. This is particularly efﬁcient for generating point muta-
tions and deletions in the full-length antigenomic cDNA where
convenient restriction enzyme sites are not available. This system
will be useful for manipulation of RSV and may be useful for
rescue and mutagenesis of Pneumovirinae or other RNA viruses
with cDNA that is difﬁcult to clone.
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Fig. 3. A2-K-line19F encoded mKate2 serves as a marker for RSV infected cells. (A) HEp-2 cell monolayer cultures were infected with indicated virus at MOI 1.0 and
incubated for 48 h. RSV F protein was detected using indirect immunostaining and cell nuclei were detected using TO-PRO-3 iodide stain. RSV F is in green, mKate2 in red,
and nuclei in blue. (B) HEp-2 cell culture monolayers were inoculated with indicated virus at MOI 3.0 and incubated for 24 h. Panels show scatter plots from representative
samples with a percentage of total cells detected as indicated for each quadrant.
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Plasmids
Using published RSV sequences, we designed an antigenomic
cDNA of a chimeric RSV strain A2 harboring the F gene of RSV
strain line 19 (Table 1) (Moore et al., 2009). The cDNA was
synthesized (GeneArt, Regensberg, Germany) in three separate
fragments. In order 50 to 30, the ﬁrst fragment contains a T7
promoter, a hammerhead ribozyme, RSV leader sequence, and
genes encoding monomeric Katushka 2 (a red ﬂuorescent protein
mKate2) (Shcherbo et al., 2009), RSV NS1, NS2, N, P, M, and a
portion of SH ﬂanked by appropriate RSV gene start, intergenic,
and gene end sequences. This fragment is ﬂanked by restriction
sites BstBI and SacI. The second segment is ﬂanked by restriction
sites SacI and ClaI, and it contains the continuation of the SH gene
followed by the RSV G, RSV line 19 strain F, and M2 genes, as well
as a portion of the L gene. The third fragment contains the rest of
the L gene followed by the RSV A2 trailer sequence, the hepatitis
delta virus ribozyme, and a T7 terminator. This segment is ﬂanked
by ClaI and MluI restriction enzyme sites. We obtained a BAC
vector (pKBS2) harboring the mouse adenovirus type 1 (MAV-1)
genome (Katherine Spindler, University of Michigan). The MAV-1
DNA was removed, and the three RSV cDNA fragments were
inserted sequentially in the BAC vector. This synthetic, mKate2-
expressing BAC-RSV construct was termed pSynkRSV-line19F. The
nucleotide features contained in pSynkRSV-line19F are shown in
Table 1 with references.
We developed mammalian expression vectors for the RSV N, P,
M2-1, and L proteins (Dochow et al., 2012). Brieﬂy, the sequences of
the wild-type genes encoding these proteins in the RSV strain A2
were obtained from GenBank. We optimized the sequences for
expression using computational algorithms to reduce the use of
rare codons, occult splice sites, mRNA instability sequences, and
RNA secondary structural elements. The optimized cDNA sequences
were synthesized (GeneArt) and then cloned into the pcDNA3.1mammalian expression plasmid vector (Invitrogen, Grand Island,
New York, USA). Plasmids were used to transfect 293F cells, then
cells were ﬁxed and permeabilized for immunoﬂuorescence stain-
ing or lysed for analysis of expression by SDS-PAGE and Western
blot. Each of the proteins were expressed in mammalian cells with
the predicted molecular weight, as detected using polyclonal
antisera to RSV (data not shown). The four helper plasmids
pTM1-N, pTM1-P, pTM1-M2-1, and pTM1-L, each containing the
gene under control of a T7 promoter, were obtained from Peter
Collins (Collins et al., 1995).
cDNA stability
To determine the stability of RSV antigenomic cDNA in cloning
plasmids, a high-copy number vector (pMA, GeneArt) or single-
copy number (pKBS2) vector containing the same piece of RSV
antigenomic cDNA (corresponding to nucleotides 5382–9949 in
pSynkRSV-line19F) were transformed into NEB-10b (New Eng-
land BioLabs, Ipswitch, Massachusetts, USA) or One Shot Stbl-3
(Invitrogen) E. coli following manufacturer’s protocols. E. coliwere
cultured at 321 C. The high-copy number vector was the GeneArt
vector pMA, while the single-copy vector was pKBS2, as described
above. pMA has a ColE1 origin of replication and carries an
ampicillin resistance gene. Ten transformants from each were
selected at random, and restriction digests were used to deter-
mine if plasmids contained in the transformants displayed the
expected digestion pattern.
RSV-BAC mutations
We used recombination-mediated mutagenesis to generate a
point mutation in the F gene of pSynkRSV-line19F. Our protocol
was based a method using positive and negative selection of the
galactokinase expression cassette (galK) (Warming et al., 2005).
The galK cassette was ampliﬁed from plasmid pgalK using primers
Fig. 4. In vitro and in vivo growth characteristics of A2-K-line19F and A2-RL-line19F. (A and B) Growth curves of A2 (’), A2-line19F (), and A2-K-line19F (O) in HEp-2 cell
monolayer cultures infected at MOI 2.0 (A) or MOI 0.1 (B). (C) Growth curve of A2-K-line19F (’) and A2-RL-line19F () in HEp-2 cell monolayer cultures infected at MOI 0.5.
(D) Viral titers and luciferase activity in HEp-2 cell monolayer cultures infected with A2-RL-line19F at anMOI of 0.5. Titers are indicated by plaque forming units per mL () and
luciferase activity is indicated by counts per second (O). Data for panels A–D are indicated as mean7SEM. (E) BALB/c mice were infected with 5105 PFU/mouse (5 mice per
group) of A2-line19F, A2-K-line19F, or A2-RL-line19F and viral load was determined day 4 post-infection via immunodetection plaque assay. *P¼0.05, **P¼0.01 by ANOVA.
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GAAGCACACCACCTGTTGACAATTAATCATCGGCA-30 and 557galK R
50-ACTAAATGCAATATTATTTATACCACTCAGTTGATCCTTGCTTAGT-
GTGATCAGCACTGTCCTGCTCCTT-30. pSynkRSV-line19F homology
arms are in bold and galK sequence is italicized. The PCR
conditions were 94 1C denaturation for 30 s followed by 30 cycles
(94 1C for 15 s, 60 1C for 30 s, and 72 1C for 1 min) and a ﬁnal
6 min, 72 1C extension. The resulting double stranded product
was the galK cassette ﬂanked by RSV homology arms. Upon
recombination, the galK cassette replaced the nucleotide to be
changed in pSynkRSV-line19F. For the second recombination step
to replace galK with the desired mutation, we used annealed
oligonucleotide adapters with the following sequences: 557inF50-CATTAATTGCTGTTGGACTGCTCCTATACTGTAAGGCCAGAAGCA-
CACCAGTCACACTAAGCAAGGATCAACTGAGTGGTATAAATAATAT-
TGCATTTAGT-30 and 557inR 50-ACTAAATGCAATATTATTTATAC-
CACTCAGTTGATCCTTGCTTAGTGTGACTGGTGTGCTTCTGGCCTTA-
CAGTATAGGAGCAGTCCAACAGCAATTAATG-30. 557inF and 557inR
are entirely homologous to pSynkRSV-line19F except for the bold
nucleotide, which designates the mutation.
The NS1 and NS2 genes were deleted from a version of the BAC-
RSV without the gene for mKate2. The primers for galK ampli-
ﬁcation from pgalK were NS1startF 50–ATAAGAATTTGATAAGTAC-
CACTTAAATTTAACTCCCTTGGTTAGAGATGCCTGTTGACAATTAATCA-
TCGGCA-30 and NS2stopR 50-TATGCATAGAGTTGTTGTTTTAGATT-
GTGTGAATATTGTGTTGAAATTTATCAGCACTGTCCTGCTCCTT-3. RSV
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Fig. 5. Recombination-mediated mutagenesis derived mutant viruses. Western blots of cell lysates from Vero cell monolayer cultures infected with A2-line19F or
A2-line19FDNS1/NS2. Polyclonal antisera for NS1 or NS2 were used to detect protein expression. Anti-RSV N was used to detect RSV N as a loading control.
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italicized. The PCR conditions were the same as described above.
To complete the NS1/NS2 deletion and replace galK, the follow-
ing oligonucleotides were annealed and used for recombination.
dNS12F 50-ATAAGAATTTGATAAGTACCACTTAAATTTAACTCCCTTGG-
TTAGAGATGGCTCTTAGCAAAGTCAAGTTGAATGATACACTCAACAAA-
GATCAACTTCT-30 and dNS12R 50-AGAAGTTGATCTTTGTTGAGTGTA-
TCATTCAACTTGACTTTGCTAAGAGCCATCTCTAACCAAGGGAGTTAA-
ATTTAAGTGGTACTTATCAAATTCTTAT-30. dNS12F and dNS12R are
entirely homologous sequences to the RSV antigenome.
A double recombination-PCR strategy was employed to gen-
erate cDNA copies of pSynkRSV-LucRen in pSynkRSV-line19F. First,
individual segments of pSynkRSV-line19F ﬂanking the luciferase
insertion site and harboring unique BstBI and AvrII restrictions
sites were ampliﬁed using oligonucleotide primer pairs 50–CCCA-
GGCCGT GCCGGC/50–GCTAAGCAAGGGAGTTAAATTTAAGTGG. The
Renilla luciferase gene was ampliﬁed from pGL4.74[hRluc/TK]
(Promega, Madison, Wisconsin, USA) with oligonucleotide primer
pairs 50–CCACTTAAATTTAA CTCCCTTGCTTAGCATGGCTTCCAA-
GGTGTACG/50–CTGTTAAGTTTTTAATAACTAT AATTGAATACTCAC-
TGCTCGTTCTTCAGCACGC (the bold nucleotides are complemen-
tary to the RSV genomic sequences ﬂanking the insertion site). In
two consecutive PCR reactions, the luciferase-encoding amplicon
was then recombined with the pSynkRSV-line19F-derived seg-
ments, and the ﬁnal amplicon subcloned into the pCR2.1-TOPO
(Invitrogen) vector. Transfer of BstBI/AvrII segments harboring
the luciferase gene into the similarly opened pSynkRSV-line19F
produced pSynkRSV-LucRen.
We modiﬁed the protocol from Warming et al. for our
recombination-mediated mutagenesis procedure (Warming
et al., 2005). Most notably, we used 50 mL electrocompetent
E. coli and 100–200 ng of PCR product or annealed oligonucleotides
for each electroporation event. In addition, E. coli containing
pSynkRSV-line19F routinely took 4–5 days to form colonies on
both positive and negative galK selection plates.
Recombinant virus recovery
Recombinant viruses were recovered by modifying the proto-
col from previous reports (Buchholz et al., 1999; Collins et al.,
1995). BHK cells constitutively expressing the T7 polymerase
(BSR-T7/5 cells) were transfected with BAC-RSV plasmids as well
as the sequence-optimized helper plasmids encoding N, P, M2-1,
and L, all under T7 control (Buchholz et al., 1999). Using
Lipofectamine 2000 (Invitrogen), the plasmids were transfected
at concentrations of 0.8 mg, 0.4 mg, 0.4 mg, 0.4 mg, and 0.2 mg,
respectively. Prior to transfection, BSR-T7/5 cells were maintained
in Glasgow’s minimal essential media (GMEM, Invitrogen) sup-
plemented with 10% FBS, 1% penicillin, streptomycin sulfate,
amphotericin B solution (Invitrogen), and 2% minimal essential
amino acids (Invitrogen), with 1 mg/mL Geneticin (Invitrogen)added every other passage. Cells were plated to be conﬂuent in
6 well plates at the time of transfection. Cells were incubated
with transfection complexes of 500 mL at room temperature for
2 h on a rocking platform. Following this incubation, 500 mL of
GMEM supplemented as described above, except that FBS con-
centration was 3%, was added to each well and the cells were
incubated overnight at 37 1C. The next morning, the transfection
complexes were removed from the wells and replaced with 2 mL
of GMEMþ3% FBS. Cells were passed into 25 cm2 ﬂasks 2 days
post-transfection, and every 2–3 days following until cytopathic
effect was seen, at which time the cells were scraped from the
ﬂasks, aliquoted, and frozen. After thawing to release to virus, the
cells and cell debris were pelleted at 1800 g for 5 min at 4 1C,
and the supernatant was used to infect subconﬂuent HEp-2 cell
monolayer cultures in order to propagate recovered virus.
RSV minigenome luciferase reporter assay
Construction of the RSV minigenome reporter plasmid has
been described (Dochow et al., 2012). BSR-T7/5 cells were
transfected with the RSV minigenome reporter and the helper
plasmids encoding N, P, M2-1, and L in either sequence-optimized
or non-optimized forms. Using Lipofectamine 2000, the plasmids
were transfected in the following quantities: 0.8 mg minigenome,
0.4 mg N, P, and M2-1, and 0.2 mg L. The transfection procedure
was identical to that for recombinant virus recovery, except that
two hours post-transfection 1.5 ml of GMEM supplemented with
3% FBS was added to cells. Approximately 24 h post-transfection,
the supernatant was removed, the cells washed once in phos-
phate buffered saline (PBS), and lysed in 300 mL 1 reporter lysis
buffer (Promega). Samples were diluted 1:100 and luciferase
activity was determined using a Perkin Elmer Top Count scintilla-
tion and luminescence counter.
Virus growth curves and quantiﬁcation of lung viral load
Subconﬂuent HEp-2 cell monolayer cultures in 6-well plates
were infected in triplicate with RSV A2, A2-line19F, or A2-K-
line19F at an MOI of 0.1 or 2.0. The virus was adsorbed for one
hour at room temperature with rocking. Unbound inoculum was
washed off with PBS and EMEM supplemented with 10% FBS and
1% penicillin, streptomycin sulfate, amphotericin B solution (Invi-
trogen) was added to the cells. Samples of the supernatant were
taken at 12, 24, 48, and 72 h post-infection and frozen until
plaque titration by immunodetection plaque assay (Stokes et al.,
2011). For the A2-RL-line19F growth curve, HEp-2 cell monolayer
cultures were infected at an MOI of 0.5. 12, 24, 48, 72, and 96 h
post-infection, cells were washed in PBS and either 1 ml of
MEM or 200 mL of Renilla-Glo lysis buffer (Promega) was added.
The cells in MEM were scraped and frozen until plaque titration.
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activity was determined using the Renilla-Glo system (Promega).
To determine lung viral load, 6–8 week old BALB/c mice (The
Jackson Laboratory, Bar Harbor, Maine, USA) were infected intra-
nasally with 5105 pfu of RSV per mouse as described (Moore
et al., 2009). On day four post-infection, the left lung was
harvested and viral load was determined as described previously
(Stokes et al., 2011). The procedures for all experiments involving
mice were approved by the Emory University Institutional Animal
Care and Use Committee.
NS1/NS2 Western blotting
Vero cells maintained in EMEM supplemented with 10% FBS
and antibiotic/antimycotic were infected with A2-line19F and A2-
line19FDNS1/NS2 and infected cell lysates were harvested 24 h
post-infection in RIPA buffer (Sigma-Aldrich, St. Louis, Missouri,
USA). Lysates were mixed 1:1 with Laemmli sample buffer prior
to loading on SDS 4%–20% polyacrylamide gels (Bio-Rad, Hercules,
California, USA). Proteins were transferred to polyvinylidene
ﬂuoride membranes. NS1 and NS2 were detected using polyclonal
rabbit sera raised to recombinant NS1 or NS2 proteins. The NS2
antisera slightly cross-react with NS1. Secondary incubation with
horse radish peroxidase (HRP) coupled goat anti-rabbit (Jackson
Immunoresearch Laboratories, West Grove, Pennsylvania, USA)
IgG antibodies followed by chemiluminescent detection using
SuperSignal West Femto Substrate (Thermo Scientiﬁc, Rockford,
Illinois, USA) on a ChemiDoc imaging system (Bio-Rad) enabled
visualization of proteins. Antibodies were stripped from mem-
branes using Restore Western Blot Stripping Buffer (Thermo
Scientiﬁc) and re-probed using an anti-N RSV antibody (clone
D14, a gift from Dr. Ed Walsh) and HRP-coupled donkey anti-
mouse secondary (Jackson Immunoresearch Laboratories) (Walsh
and Hruska, 1983).
Immunoﬂuorescence microscopy
HEp-2 cell monolayer cultures on 6-well plates were inocu-
lated with RSV at MOI 1.0. 48 h later cells were ﬁxed with 3.7%
(w/v) paraformaldehyde in PBS for 10 min then permeabilized
with 0.3% (w/v) Triton X-100 and 3.7% paraformaldehyde in PBS
for 10 min at RT. After ﬁxation, cells were blocked in 3% (w/v) BSA
in PBS for 60 min followed by addition of primary antibody in the
blocking solution for 60 min. Cells then were washed three times
in PBS, and species-speciﬁc anti-IgG Alexa Fluor conjugated
antibodies (Invitrogen) were added at a dilution of 1:1000 in
block solution for 60 min to detect primary antibodies. Cells were
washed three times in PBS and ﬁxed on glass slides using Prolong
Antifade kit (Invitrogen). All steps were performed at room
temperature. Images were obtained on a Zeiss inverted LSM510
confocal microscope using a 63 /1.40 Plan-Apochromat oil
lens. Anti-RSV F protein humanized mouse monoclonal antibody
(palivizumab; MedImmune) was obtained from the Vanderbilt
Pharmacy, and TO-PRO-3 iodide stain (Invitrogen) was used to
visualize the nucleus.
Flow cytometric assay for quantitative surface expression of RSV F
protein
HEp-2 cell monolayer cultures on 6-well plates were inocu-
lated with RSV at MOI 3.0. After 24 h, cells were treated with
20 mM EDTA in PBS to form a single cell suspension. Cells were
washed twice in wash buffer (2% FBS in PBS) and then incubated
with RSV F-speciﬁc monoclonal antibody (palivizumab) at
1 mg/mL for 30 min at RT. Cells again were washed twice with
wash buffer and immunostained with an Alexa Fluor 488 labeledgoat anti-mouse secondary antibodies at a ﬁnal concentration of
2 mg/mL. Cells were washed twice in wash buffer and analyzed on
a 5-laser LSRFortessaTM ﬂow cytometer (Becton Dickinson, Franklin
Lakes, New Jersey, USA) in the Vanderbilt Medical Center Flow
Cytometry Shared Resource. Data analysis was performed using
FlowJo version 7.6.5 (Treestar Inc., Ashland, Oregon, USA).
Statistical analyses
Groups were compared by one way analysis of variance (ANOVA)
and Tukeymultiple comparison tests unless otherwise noted. Po0.05
was considered signiﬁcant.Disclosure statement
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